Abstracts tagged "atherosclerosis and cardiovascular disease"

Abstract Number: 2644 • 2014 ACR/ARHP Annual Meeting
Carotid Intima-Media Thickness and Plaque in Mexican Mestizos with Systemic Lupus Erythematosus: A Case-Control Study
Iris J. Colunga-Pedraza¹, Dionicio A. Galarza-Delgado¹, Alberto Cardenas-de La Garza¹, Ana L. Sanchez-Nuñez¹, Samantha L. Segarra-Linares¹, Rocío A. Carrillo-Palacios¹, David Vega-Morales¹, Fernando Góngora-Rivera² and Mario Alberto Garza-Elizondo¹, ¹Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ²Neurology., Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose Systemic lupus erythematosus (SLE) patients are at risk of premature cardiovascular disease (CVD). The specific reason of this situation is still debatable. Subclinical atherosclerosis…
Abstract Number: 1647 • 2014 ACR/ARHP Annual Meeting
Relationship Between Apom/S1P Levels and Atherosclerosis in Women with Systemic Lupus Erythematosus
Sonali Narain¹, Sylvain Galvani², Christina Christoffersen³, Peiying Yang⁴, Maureen A. McMahon⁵, Timothy Hla² and Jane E. Salmon¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Vascular Biology, Weill Cornell College of Medicine, New York, NY, ³Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴Gen Oncology Research, University of Texas MD Anderson Cancer Center, Houston, TX, ⁵Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: SLE patients are at risk for atherosclerotic cardiovascular disease (ASCVD). In some SLE patients, high density lipoprotein (HDL) has impaired vasoprotective effects, and this…
Abstract Number: 865 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Events Prior to or Early after Diagnosis of SLE
Murray B. Urowitz¹, Dafna D. Gladman¹, Nicole Anderson², Dominique Ibanez³ and Systemic Lupus International Collaborating Clinics (SLICC)⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Division of Rheumatology, University of Toronto, Toronto Western Hospital (Coordinating Center), Toronto, ON, Canada
Background/Purpose: A large multicenter multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. Previous studies have shown a history of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].